Parkinson disease (PD) is no longer considered a complex motor disorder but rather a systemic disease with variable nonmotor deficits that may include impaired olfaction, depression, mood and sleep disorders, and altered cortical function. Increasing evidence indicates that multiple metabolic defects occur in regions outside the substantia nigra, including the cerebral cortex, even at premotor stages of the disease. We investigated changes in gene expression in the frontal cortex in PD patient brains using a transcriptomics approach. Functional genomics analysis indicated that cortical olfactory receptors (ORs) and taste receptors (TASRs) are altered in PD patients. Olfactory receptors OR2L13, OR1E1, OR2J3, OR52L1, and OR11H1 and taste receptors TAS2R5 and TAS2R50 were downregulated, but TAS2R10 and TAS2R13 were upregulated at premotor and parkinsonian stages in the frontal cortex area 8 in PD patient brains. Furthermore, we present novel evidence that, in addition to the ORs, obligate downstream components of OR function adenylyl cyclase 3 and olfactory G protein (G>olf), OR transporters, receptor transporter proteins 1 and 2 and receptor expression enhancing protein 1, and OR xenobiotic removing UDP-glucuronosyltransferase 1 family polypeptide A6 are widely expressed in neurons of the cerebral cortex and other regions of the adult human brain. Together, these findings support the concept that ORs and TASRs in the cerebral cortex may have novel physiologic functions that are affected in PD patients.
INTRODUCTION
Odorant and pheromone signaling make up a highly complex system that permits chemical communication among species and allows individuals of a particular species to gain information about vital functions such as the availability of food, sexual status, mating, reproduction, breeding, newborn imprinting, territorial marking and homing, and navigation. The repertoire of receptors from insects to fish and mammals occupies a major part of the genome at the time that putative ligands number in the thousands (1Y5).
Odorant activation of sensory olfactory neurons in mammals is mediated by activation of G proteins and adenylyl cyclase (AC), increased intracellular concentration of cyclic adenosine monophosphate (cAMP), activation of cAMP-gated channels, and neuron depolarization (6Y13). The specific olfactory G protein is G>olf (14) , and the olfactory cyclic nucleotideYgated cation channel is specifically linked to olfaction (15) . Mice null for the expression of either G olf or adenylyl cyclase 3 (AC3) are anosmic, thus indicating that both G>olf and AC3 are obligate components of olfactory function in sensory olfactory neurons (16, 17) .
Olfactory or odorant receptors (ORs) have been identified as a large family of G proteinYcoupled receptors, having conserved transmembrane motifs in common (18Y20). The number of functional OR genes and OR pseudo-genes is variable among species, but of about 30,000 genes in the mouse ge''Ectopic'' localization of ORs in nonolfactory tissues has recently become a focus of attention and has raised questions about putative nonodorant-related functions of ORs in various nonolfactory regions. For example, ORs have been detected in germinal cells, testis, kidney, heart, and lung, among others (24Y29), and expression of the olfactory signaling system (G>olf and AC3) has been reported in the kidney (30) . A number of ORs (M71, I7, C6, P2, and OR3) have also been detected in mouse cerebral cortex (31) , but the concomitant occurrence of G>olf and AC3 that might ascribe a function to ORs in mammalian cerebral cortex has not been documented. Whether OR expression occurs in the cerebral cortex in species other than the mouse and, particularly, in humans is not known.
A long-standing focus of our laboratory lies in gaining insight into cortical molecular events in early Parkinson disease (PD) (32, 33) . Toward this aim, we performed transcriptomic analysis of frontal cerebral cortex of premotor and parkinsonian stages of postmortem brain samples from PD patients and agematched controls. We encountered unexpected dysregulation of a group of genes corresponding to ORs in PD patients. Therefore, the rationale and objectives of the present work were to 1) perform accurate functional enrichment analysis of microarray results; 2) validate candidate dysregulated OR genes in PD by polymerase chain reaction (PCR); 3) study the expression of other candidate chemoreceptors (i.e. taste receptors [TASRs] ) in frontal cortex and their possible modifications in PD (to determine the specificity of OR dysregulation); 4) identify, map, and determine the cellular distribution of several ORs and the obligate mediators G>olf and AC3 in the frontal cortex; and 5) detect putative OR transporters and specific molecules involved in the detoxification of various xenobiotic and endobiotic compounds linked to OR signaling.
MATERIALS AND METHODS

Case Material
Brain tissue was obtained from the Institute of Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank) and the Biobank of Hospital Clinic-IDIBAPS following the guidelines both of Spanish legislation on this matter and of the local ethics committee. The postmortem interval between death and tissue processing was between 3 and 14 hours in all cases. One hemisphere was immediately cut in 1-cm-thick coronal sections, and selected areas of the encephalon were rapidly dissected, frozen on metal plates over dry ice, placed in individual air-tight plastic bags, numbered with water-resistant ink, and stored at j80-C until use for biochemical studies. The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks for morphologic studies. A summary of the cases and their use in the different methods used is shown in Table 1 .
The neuropathologic diagnosis of PD was based on the classification of Braak but excluded atypical cases in which no graded pathology from the medulla oblongata, pons, and midbrain to limbic structures was identified (34) . The PD series included Braak neuropathologic stages 3 (n = 7), 4 (n = 16), and 5 (n = 12). Approximately 30% of the cases did not have a clinical history of parkinsonism and were categorized as ''premotor'' stages (7 PD3; 4 PD4) (35) . The olfactory bulb was involved in every case, showing >-synuclein deposits in scattered neurons and neurites; >-synuclein deposits in the amygdala were found in cases at stage 4 and 5 and in the entorhinal cortex in cases at stage 5. Only pure cases were chosen for study; cases with mixed pathologies (i.e. associated tauopathies and vascular diseases) were excluded. Finally, control cases (n = 19) did not have histories of a neurologic or mental disorder and the neuropathologic postmortem study revealed no brain lesions, including neurofibrillary tangles with the exception of a few (if any) that were restricted to the entorhinal cortex; there were no A-amyloid deposits or abnormal protein aggregates in any region. Sex representation was similar in control and diseased brains (8 women and 11 men in the control group and 16 women and 19 men in the PD group).
In addition, to analyze the vulnerability of the proteins under study to postmortem delay, unrelated selected samples of the frontal cortex (area 8) of 3 control cases were processed mimicking an artificial postmortem delay (36) . For this purpose, the brains were obtained 3 hours after death, and samples of the left frontal cortex were rapidly frozen at j80-C or stored at 4-C for different periods and then frozen at 6, 9, 24, and 48 hours after death. These samples were only used for Western blot studies, and they were run in parallel in the same gels.
RNA Purification
The purification of RNA was carried out with RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) following the protocol provided by the manufacturer. During purification, samples were treated with RNase-free DNase Set (Qiagen) to avoid later amplification of genomic DNA. The concentration of each sample was obtained from A260 measurements with Nanodrop 1000. RNA integrity was tested using the Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA). Values of RNA quality (RIN values) were from 7 to 8.8.
Retrotranscription Reaction
The retrotranscriptase reaction was carried out using a High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA) following the protocol provided by the supplier. Parallel reactions for each RNA sample were run in the absence of MultiScribe Reverse Transcriptase to assess the degree of contaminating genomic DNA.
Whole-Transcript Expression Arrays
RNA samples from the frontal cortex (area 8) of control (n = 7) and PD (n = 11) cases were analyzed using the Affymetrix microarray platform and the Genechip Human Gene 1.1 ST Array. Parkinson disease cases included premotor stages (n = 4) and cases with parkinsonism (n = 7) ( Table 1 ). This array analyzes gene expression patterns on a whole-genome scale on a single array, with probes covering several exons on the target genes. Starting material was 200 ng of total RNA of each sample. Quality of isolated RNA was first measured by Bioanalyzer Assay (Agilent). Sense ssDNA suitable for labeling was generated from total RNA with the Ambion WT Expression Kit from Ambion (Carlsbad, CA), according to the manufacturer's instructions. Sense ssDNA was fragmented, labeled, 
Microarray Data Normalization and Differential Expression Analysis
Preprocessing of raw data and statistical analyses were performed using Bioconductor packages in R programming environment (37) . We read CEL files from Affymetrix arrays, corrected the background, and summarized and normalized the data with the robust microarray A method implemented in the Bioconductor Limma package (38) . Furthermore, we estimated the fold change and SEs by fitting a linear model (using the lmFit function in Limma package) for each gene given the groups of arrays. Genes with empirical Bayes t test p values at a level of 0.05 were selected and corrected by calculating the false discovery rate p G 0.05 (adjusted probability [probadj] ). The microarray experiment was deposited in the Array Express Database under accession number E-MTAB-1194.
Functional Enrichment Analysis
To evaluate which pathways or functional categories were enriched in PD samples, we followed a similar strategy as shown elsewhere (39) . Briefly, we computed the Gene Set Enrichment Analysis from Limma package and Hypergeometricbased (HYPERG) tests from GOstats package (40) . We used p G 0.05 as the cutoff point to determine whether Gene Ontology (GO) term or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were significantly enriched.
GeneSetTest function from Limma package tests whether a set of genes is enriched for differential expression. Its principle is the same as that of the Gene Set Enrichment Analysis (41) , but the statistical tests used are different. It is based on a set of probe-wise t statistics arising for microarray analysis. We computed 3 different tests: 1) upregulated genes with positive t statistics (G.UP); 2) downregulated genes with negative t statistics (G.DOWN); and 3) upregulated or downregulated genes as a whole (G.MIXED). We used GOstats package to determine gene ontology terms and KEGG pathways enriched in the subset of genes with differential expression in PD compared with control groups at p G 0.05 adjusted probability.
TaqMan PCR
Cases analyzed included 10 controls (7 men and 3 women) and 20 PD cases (12 men and 8 women) ( Table 1) . TaqMan PCR assays for each gene were performed in duplicate on cDNA samples in 384-well optical plates using an ABI Prism 7900 Sequence Detection System (Applied Biosystems). For each 20-KL TaqMan reaction, 9 KL cDNA was mixed with 1 KL 20Â TaqMan Gene Expression Assays and 10 KL of 2Â TaqMan Universal PCR Master Mix (Applied Biosystems). The reactions were carried out using the following parameters: 50-C for 2 minutes, 95-C for 10 minutes, and 40 cycles of 95-C for 15 seconds and 60-C for 1 minute. Finally, all TaqMan PCR data were captured using the Sequence Detection System software (SDS version 1.9, Applied Biosystems). Probes used in this study are shown in Table 2 .
Samples were analyzed with the double delta CT ($$CT) method. Delta CT ($CT) values represent normalized target gene levels with respect to the internal controls glucuronidase-A (GUSA), X-prolyl aminopeptidase (aminopeptidase P) 1 (XPNP EP1), and alanyl-tRNA synthetase (AARS). These novel reference genes were selected because they are very efficient in replicating microarray target gene expression in human postmortem brain tissue (42, 43) . Double delta CT values were calculated as the $CT of each test sample minus the mean $CT of the calibrator samples for each target gene. The fold change was calculated using the equation 2
. Results were analyzed by 2-way analysis of variance followed by Student t test when : GTGAGGCCCCTGCACTATTGATCTT  OR4F4: TATACACACTGAGGAACAAAGACAT  TAS2R14: TTTGTCCCTGGCAATGTTTCTTCTC  TAS2R50: AGTCCTAGGAGGCTGCGGAATGACC  TAS2R10: ACCACAGCCATCTATCCCTGGGGTC  TAS2R13: CACCATTTACTGTGGCCTTCATCTC  TAS2R4: TACATCACGCTTAGCCAGGCATCAC  TAS2R5: TTTCTTGTTTCCTCTGGGATGCTGA Probes for normalization were A-glucuronidase (GUSB), X-prolyl aminopeptidase P1 (XPNPEP1), and alanyl-tRNA synthetase (AARS). 
Immunohistochemistry and Immunofluorescence
The immunohistochemical study of ORs was carried out in 4-Km-thick dewaxed paraffin sections and 8-Km-thick paraformaldehyde-fixed cryoprotected sections. Immunofluorescence was conducted only in paraffin sections in 8 controls and 13 PD brains ( Table 1 ). The following regions were examined: hippocampus proper, dentate gyrus, hilus, entorhinal cortex, inferior temporal cortex, frontal cortex area 8, orbitofrontal cortex, dorsomedial thalamus, substantia nigra, motor ocular nucleus, anterior pontine nuclei, and cerebellar vermis. Sections processed for immunofluorescence were pretreated with a saturated solution of Sudan black B (Merck, Darmstadt, Germany) for 15 minutes to block the autofluorescence of lipofuscin granules present in cell bodies and then rinsed in 70% ethanol and washed in distilled water. In all cases, the sections were boiled in citrate buffer (20 minutes) to retrieve antigenicity. Endogenous peroxidases were blocked by incubation in 10% methanolY1% H 2 O 2 solution (15 minutes) followed by 3% normal horse serum solution. Anti-OR antibodies were named according to the corresponding targets: rabbit polyclonal anti-OR2H2 (OR2H2, LS-A4840; MBL International, Woburn, MA), anti-OR2A4 (OR2A4, ab 97486; Abcam, Cambridge, UK), anti-OR6K3 (OR6K3; MBL International), all used at a dilution of 1:100; polyclonal rabbit antibody antiYadenylyl cyclase 3 (ADCY3) (ab 14778; Abcam) diluted 1:100; and antiYProtein G>olf (sc 55545; Santa Cruz Biotechnology, Santa Cruz, CA), used at a dilution of 1:50. Additional sections were immunostained with polyclonal rabbit antibodies against receptor transporter proteins 1 and 2 (anti-RTP1 and anti-RTP2: ab 107963 and ab103637 Abcam, respectively) both diluted at 1:50 and against receptor expression enhancing protein 1 (REEP1, ab105583; Abcam) used at a dilution of 1:50. Rabbit polyclonal antibody against UDP-glucuronosyltransferase 1 family polypeptide A6 (UGT1A6) (309014, OriGene, Rockville, MD) was used at a dilution 1:50. After incubation with the primary antibody, the sections were incubated with EnVision + system peroxidase (Dako, Glostrup, Denmark) for 30 minutes at room temperature. The peroxidase reaction was visualized with diaminobenzidine, NH 4 NiSO 4 , and H 2 O 2 . The immunoreaction results in a bluegray precipitate. Sections were not counterstained with hematoxylin but were dehydrated and coverslipped for microscopic observation. After incubation with the primary antibody, sections processed for immunofluorescence were incubated with Alexa488 (1:400; Molecular Probes, Eugene, OR) fluorescence secondary antibody. Nuclei were stained with DRAQ5 (1:2000; Biostatus, Inc., Leicestershire, UK). After washing, the sections were mounted in Immuno-Fluore mounting medium (ICN Biomedicals, Irvine, CA), sealed, and dried overnight. Sections were examined with a Leica TCS-SL confocal microscope.
The specificity of the immunoreaction was tested by incubating sections without the primary antibodies; these sections were negative. Because no antigenic peptides were available for preabsorption control studies, specificity of the antibodies was tested by the demonstration of unique band patterns at the appropriate molecular weight in Western blots.
Selection of the antibodies was based on their commercial availability and adequate immunostaining. Some tested antibodies did not work on paraffin and cryoprotected sections but on Western blots; others were only useful for Western blotting; others gave several bands and Western blots; others did not function at all and were not used in the present work. Only antibodies exhibiting convincing immunoreactivity in tissue sections were selected for study. Several procedures to enhance antigen retrieval were assessed, including citrate buffer, citrate-EDTA, Tris-buffered salineYEDTA, TRis buffer, and formic acid; optimal results for both paraffin and cryoprotected sections were obtained after boiling the sections in citrate buffer. Optimal concentrations were determined after trying different dilutions for each antibody.
Gel Electrophoresis and Western Blotting
Samples of the frontal cortex (area 8) (0.1 g) of the 3 unrelated control cases with artificial postmortem delay were homogenized with a glass homogenizer in RIPA lysis buffer (50 mmol/L Tris/HCl buffer, pH 7.4 containing 2 mmol/L EDTA, 0.2% Nonidet P-40, 1 mmol/L phenylmethylsulfonyl fluoride, protease, and phosphatase inhibitor cocktails (Roche Molecular Systems, Pleasanton, CA) and then centrifuged at 4-C for 15 minutes at 13,000 rpm (ultracentrifuge Beckman with 70Ti rotor). Protein concentration was determined by BCA method (Thermo Scientific, Waltham, MA). Samples containing 25 Kg of protein were loaded onto 12% acrylamide gels. Proteins were separated in sodium dodecyl sulfate (SDS)Y polyacrylamide gel electrophoresis and electrophoretically transferred to nitrocellulose membranes (200 mA per membrane, 90 minutes). Nonspecific binding was blocked by incubation in 5% albumin in PBS containing 0.2% Tween for 1 hour at room temperature. After washing, the membranes were incubated at 4-C overnight with one of the following antibodies in PBS containing 5% albumin and 0.2% Tween: anti-OR2H2 (MBL International), anti-OR2A4 (Abcam), anti-OR6K3 (MBL International), all diluted 1:100, and ADCY3 (Abcam). Membranes were then incubated for 1 hour with the appropriate horseradish peroxidaseYconjugated secondary antibody (1:2000; Dako), and the immune complexes were revealed with a chemiluminescence reagent (ECL, Amersham, UK).
Lipid Raft Isolation
Lipid raft fractions were isolated from the frontal cortex (area 8) of control (n = 5) and PD (n = 4) cases (Table 1) , as described with slight modifications (44, 45) . Briefly, 0.1 g of brain cortex was homogenized at 4-C in 8 volumes of isolation buffer (50 mmol/L Tris-HCl, pH 8.0, 10 mmol/L MgCl 2 , 0.15 mol/L NaCl) containing 1% Triton X-100 and 5% glycerol, 20 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 5 mmol/L Amercaptoethanol, 1 mmol/L phenylmethylsulfonyl fluoride, and a cocktail of protease inhibitors (Roche Diagnostics, Barcelona, Spain) in a glass homogenizer for 5 minutes, centrifuged at 500 Â g for another 5 minutes; the supernatant was then collected and mixed in an orbital rotor for 1 hour at 4-C. Approximately 800 KL of the supernatant was mixed with an equal volume of 80% sucrose in isolation buffer and overlaid with 7.5 mL of a 36% sucrose solution and 2.7 mL of a 15% sucrose solution in isolation buffer in 10 mL ultracentrifuge tubes (Ultraclear, Beckman). Sucrose gradients were centrifuged at 150,000 Â g for 18 hours at 4-C using a Beckman SW41Ti rotor. Two-milliliter fractions were collected from the top to the bottom, and the final pellets, corresponding to nonraft fractions, were collected and resuspended in 2 mL of isolation buffer. The 6 fractions obtained were frozen at j80-C until analysis.
The purity of lipid rafts was tested using different lipid raft and nonraft protein markers in Western blot assays. Because the protocol differs from that used in total homogenates, the main differences are described below. Equal amounts of samples of the 6 raft and nonraft fractions were resuspended in SDS loading buffer (625 mmol/L Tris-HCl pH 6.8; 1% SDS, 10% glycerol, 5% A-mercaptoethanol; 0.01% bromophenol blue), heated at 95-C for 5 minutes, and loaded on 10% MiniProtean precast TGX gels (Bio-Rad) or on 12% acrylamide gels. After electrophoresis, proteins were transferred to polyvinylidene fluoride membranes and processed for Western blotting. All antibodies were diluted in 5% BLOTTO in Trisbuffered saline pH 7.2 with 0.05% Tween-20. Membranes were incubated with monoclonal mouse antiYflotillin-1 (BD Biosciences, San Jose, CA) used at a dilution of 1:1000 to identify raft fractions and with monoclonal mouse anti-Cu/Zn superoxide dismutase SOD-1 (Novocastra, Newcastle upon Tyne, UK) at a dilution of 1:1000 to identify cytosolic fractions. Later, the membranes were incubated with anti-OR2H2 (MBL International) diluted 1:100 and with ADCY3 (Abcam) diluted 1:500.
RESULTS
Global Expression Profiles Identify Dysregulation of ORs in the Frontal Cortex (Area 8) in PD
Messenger RNA samples from PD (n = 4 premotor and 7 with parkinsonism) and age-matched controls (n = 7) were hybridized to an Affymetrix Human Gene 1.1 ST Array, including more than 28,000 well-annotated genes with more than 750,000 distinct probes; 529 genes were seen to be dysregulated in PD. Modification of transcriptional profiles in PD was evidenced on the heat map representation of significantly regulated transcripts at adjusted probability of p G 0.05 (Fig. 1) .
Functional enrichment of metabolic and cell signaling pathways extracted from the KEGG revealed dysregulation of the olfactory transduction pathway (KEGG 04740) in PD compared with control samples. Pathway enrichment was analyzed with HYPERG tests to selected genes having adjusted values of p G 0.05 ( , probadj 0.00848) were the first downregulated genes located. Olfactory receptor OR4F4 was selected because it was the only putative upregulated gene, although with low significance.
Functional enrichment also revealed other families of putative chemoreceptors that were affected in the frontal cortex in PD; KEGG analysis also revealed dysregulation of taste transduction pathways (KEGG 04742) and GO 0050909, sensory perception of taste, at a value of p = 1.01 e-05 in PD (Tables 3, 4) . Validation of OR and TASR Dysregulation in PD Using TaqMan Quantitative PCR Assessment of putative dysregulated genes was conducted using cDNA from some of the same cases used for the arrays and additional cDNAs from other PD and control cases ( Table 1) . This was done to increase robustness of the results obtained in the arrays. The rationale was based on the assumption that identification of dysregulated genes common to different groups of PD cases determined by different methods further strengthens the validity of the observations. Selection of probes was carried out depending on the results of the arrays together with their commercial availability.
Eight OR genes were selected for TaqMan PCR examination: OR2J3 and OR11H1 to validate downregulated genes observed in the arrays; OR4F4 to check the only gene apparently upregulated in the arrays; and OR2L13, OR51E1, OR52L1, OR2T33, and OR2D2 as additional genes with doubtful significance in the arrays. Olfactory receptors OR52L1, OR2L13, OR51E1, OR2J3, OR52L1, and OR11H1 mRNAs were downregulated in the frontal cortex area 8 in PD cases, whereas OR2T33 and OR2D2 mRNA expression levels were similar in control and diseased samples; OR4F4 mRNA showed a significant augmentation in females with PD ( Fig. 2A) . Interestingly, most receptors were downregulated in men but not in women, with the exception of OR11H1, which was downregulated equally in both sexes and was significantly decreased in the total population analyzed ( Fig. 2A) .
Six taste receptors were also analyzed with TaqMan PCR. All of them were selected according to their putative relevance as shown in arrays: TAS2R4, TAS2R5, TAS2R14, TAS2R50, TAS2R10, and TAS2R13. Polymerase chain reaction assessment showed TAS2R4, TAS2R50, and TAS2R14 mRNA expression levels similar in control and diseased cases; however, TAS2R5 was downregulated and TAS2R10 and TAS2R13 were upregulated in the frontal cortex in PD (Fig. 2B) . Upregulation affected mainly males and downregulation occurred in males in 1 gene and females in another. Similar results were obtained using GUSA, XPNPEP1, and AARS as housekeeping genes for PCR validation.
Immunohistochemistry of ORs in Normal Human Brain
Immunohistochemistry was used to detect the presence of selected ORs for which commercial antibodies were available in paraffin sections. No commercial antibodies raised against dysregulated genes in PD were available or suitable for immunohistochemistry. Therefore, immunohistochemistry of ORs and related molecules was directed to demonstrate the presence of ORs and related proteins in the human frontal cortex rather than to complement the results of RNA arrays followed by PCR validation. Olfactory receptors OR2H2, OR2A4, and OR6K3 immunoreactivity mapped neurons of the cerebral cortex, dorsomedial thalamus, selected nuclei of the brainstem, and Purkinje cells. The intensity of the immunoreaction varied from 1 region to another. In the telencephalon, neurons of the CA1 area of the hippocampus and hilus had stronger immunoreactivity than those of the granular layer of the dentate gyrus. Moderate immunostaining was found in neurons of the entorhinal cortex, inferior temporal cortex, frontal cortex (area 8), and orbitofrontal cortex (Fig. 3AYF) . In the cerebral cortex, all layers were immunostained, the intensity largely depending on the size of neurons. Olfactory receptor immunoreactivity was also seen in the dorsomedial nucleus of the thalamus (Fig. 3G) ; OR immunoreactivity decorated the soma of Purkinje cells and granule cells to a lesser degree (Fig. 3H) . Strong OR immunoreactivity was found in selected nuclei of the brainstem including the nucleus of the motor ocular nerve in the mesencephalon, substantia nigra pars compacta and pars reticularis, and pontine nuclei (Fig. 3IYK) . In addition to neuronal soma, fine granular immunostaining was also observed in the molecular layer of the cerebellar cortex and neuropil of brainstem nuclei. Optimal staining was obtained using immunofluorescence and confocal microscopy. Similar results were obtained with the antibodies OR2H2, OR2A4, and OR6K3, although immunoreactivity was higher with antibodies anti-OR6K3 and anti-ORH2. No immunoreaction was found in parallel sections processed in parallel but without the primary antibodies (Fig. 3L) .
Olfactory receptor expression was not restricted to a single cell population, but no further attempt was made to analyze possible coexpression of different ORs in the same neuron because all the available antibodies against ORs were raised in rabbits. The general distribution of the immunostaining for every antibody was not consistent with the putative expression of a single OR per neuron, as occurs in sensory olfactory neurons.
The distribution of positive neurons was not related to any specific structure and, in particular, no relationship was observed between positive cells and blood vessels, including capillaries, and subpial and periventricular localizations. In contrast to neurons, few, if any, glial cells were immunostained in the different regions (Fig. 3K) .
Obligate Functional Components of OR Signaling in Normal Human Brain
Adenylyl cyclase 3 and G>olf immunoreactivity was low in paraffin sections but was clearly recognizable in sections processed for immunofluorescence and confocal microscopy. Fine granular immunoreactivity was seen in the cytoplasm of neurons of the hippocampus, including CA1 and hilus, dentate gyrus, neocortex, including frontal cortex, and Purkinje cells of the cerebellum (Fig. 4) . As for ORs, glial cells were rarely immunostained with anti-AC3 and anti-G>olf antibodies (data not shown).
Gel Electrophoresis and Western Blotting and Subcellular Localization of ORs, AC3, and G>olf
The possibility that postmortem delay might have interfered with protein preservation was analyzed in a paradigm of artificial postmortem delay of the same tissue samples from which small pieces were taken and stored at -80-C at different intervals. No differences in expression levels were seen at up to 24 hours of artificial postmortem delay for anti-OR2H2 and anti-AC3 antibodies, thus indicating relative preservation with postmortem delay. Each antibody recognized a net particular band pattern at the appropriate molecular weight; however, antibodies against OR2A4, OR6K3, G>olf, RTP1, RTP2, and REEP1 were not suitable for Western blotting.
Western blotting was also used to analyze the subcellular localization of ORs and AC3 in control frontal cortex area 8 following a protocol to enrich lipid rafts (Fig. 5A) . Flotillin, used as a marker of lipid rafts, was restricted to lanes 1 and 2, whereas SOD1, used as a marker of cytosolicenriched fraction, was recovered in lane 6. Interestingly, antibodies against OR2H2 revealed an expected single band of about 40 kd, whereas antibodies against AC3 showed an expected triple band between 65 and 100 kd, both restricted to lane 6 (Fig. 5A ). Cytosolic localization of ORs was further supported by immunofluorescence and confocal microscopy showing granular cytoplasmic anti-OR2H2 and anti-OR6K3 immunoreactivity (Fig. 5B) .
Localization of OR Transporters and UDP-Glucuronosyltransferase
To learn whether neurons are equipped with OR transporters that may act as shuttles to transport ORs to the membranes, immunohistochemistry, immunofluorescence, and confocal microscopy to RTP1, RTP2, and REEP1 were assessed. Best results were obtained in paraffin sections processed for immunofluorescence and, although RTP1 and RTP2 were expressed in neurons, the expression of REEP1 was stronger. Receptor Expression Enhancing Protein 1 immunofluorescence was observed in the cytoplasm of neurons of the hippocampus, dentate gyrus, entorhinal cortex, frontal cortex area 8, and inferior temporal cortex. Highest expression levels were seen in selected nuclei of the mesencephalon, including the substantia nigra and Purkinje cells of the cerebellum (Fig. 6AYH) .
Finally, immunofluorescence and confocal microscopy to UGT1A6 revealed a discrete and generalized immunoreactivity in the cytoplasm of neurons, including those of the FIGURE 2. Messenger RNA expression levels of selected olfactory (odorant) receptors (ORs) (A) and taste receptors (TASRs) (B) in the frontal cortex (area 8) in Parkinson disease (PD) and control cases as determined by TaqMan PCR assays. Significant differences are seen in the expression of OR2L13, OR51E1, OR2J3, OR52L1, and OR11H1 mRNA in PD cases compared with those in controls. All these genes are downregulated, mainly in males, in PD. Yet, expression levels of OR2T33, OR2D2, and OR4F4 mRNA in PD do not differ from levels in controls. TAS2R4 and TAS2R14 expression is not modified in PD, but TAS2R5 and TAS2R50 are downregulated, whereas TAS2R10 and TAS2R13 are upregulated in PD when compared with those in controls. TASR dysregulated expression in PD is also subjected to sex differences. C, control; PD, Parkinson disease; T, total population; M, male; F, female; * p G 0.05; ** p G 0.01; *** p G 0.001. hippocampus proper, dentate gyrus, neocortex (area 8), and Purkinje cells (Fig. 6IYL) .
Distribution of ORs, Obligate Functional Components of OR Signaling, and Transporters in PD
Immunohistochemistry to OR2H2, OR2A4, and OR6K3, AC3 and G>olf, and the transporters RTP1, RTP2, and REEP1 showed similar localization and distribution of all of these molecules in control and PD brains. No differences in the subcellular distribution, as revealed with the analysis of lipid rafts, were observed between control and PD cases regarding OR2H2 and AC3 localization in the same cytosolic fractions (data not shown). As stated above, the lack of appropriate antibodies did not permit a validation of OR dysregulation in PD at a protein level.
DISCUSSION
Tissue samples used in the present study correspond to optimally selected cases on the basis of protein and mRNA preservation; neuropathologic diagnoses were verified following the studies carried out and consensus was reached in the context of the European Brain Bank Network (European Brain Net Consortium) (36, 46Y48). Because mixed pathologies are very common in old age (49) , special attention was paid to excluding cases with combined lesions, excepting mild small blood vessel disease. More specifically, cases with PD selected for study did not have concomitant AD-like pathology, with the exception of a few neurofibrillary tangles in the entorhinal cortex (corresponding to stage I of Braak) in a few cases. Beta-amyloid pathology was absent in PD cases and control cases did not have neurologic histories or neuropathologic lesions, with the exception of a few neurofibrillary tangles in the entorhinal cortex in a few cases. This allowed for the conclusion that observed alterations were caused by particular disease states and not to the result of the sum or potentiation of associated pathologies. The frontal cortex (area 8) in PD was selected because of the amount of newly identified molecular alterations in this area in PD and related >-synucleinopathies (32, 33, 35) .
The present study reveals that ORs are widely distributed in the human CNS, including cerebral cortex, thalamus, selected nuclei of the brainstem, and Purkinje cells of the cerebellum. Interestingly, certain nuclei of the brainstem as the motor nuclei of the third cranial nerve, substantia nigra, and pontine nuclei, together with Purkinje cells, showed strong OR expression (at least for the ORs examined OR2H2, OR2A4, and OR6K3); within the cerebral cortex, the major expression occurred not only in the CA1 area and hilus of the hippocampus but also in the entorhinal cortex and neocortical areas examined. Central OR neuronal expression is accompanied by the obliged functional molecules of the OR pathway in sensory olfactory neurons, AC3, and G>olf, indicating that the OR machinery is also able to operate, at least, in selected regions of the CNS and, particularly, in the cerebral cortex. Olfactory receptor and associated molecules were overwhelmingly localized in neurons; their presence in few glial cells was unusual.
Olfactory receptor OR2H2 and AC3 (the only molecules for which antibodies were suitable for Western blot studies) are localized in cytosolic fractions in the human frontal cortex. This localization is consistent with the idea that cortical ORs may require specific mechanisms to facilitate OR translocation from the cytosol to the membranes (50, 51) . According to this rationale, cofactors of G proteinYcoupled receptors bind to specific domains of receptors, thus facilitating or inhibiting cell surface expression (52) . Receptor transporters RTP1 and RTP2, and REEP1, facilitate OR recruitment to lipid rafts (50) . The present observations show RTP1, RTP2, and REEP1 in the cytoplasm of the vast majority if not all neurons in parallel with the expression of ORs in different regions, thereby revealing that molecules specifically expressed in sensory olfactory neurons are also present in cerebral cortex and other regions of the human brain, thus enabling the traffic of ORs from the cytosol to the cellular membranes.
UDP-glucuronosyltransferases are enzymes localized in the endoplasmic reticulum and nuclear membranes involved in the detoxification of various xenobiotic and endobiotic compounds through glucuronidation of substrates, thereby facilitating their excretion (53, 54) . Several UGTs, including UGT1A6, have been reported in the olfactory epithelium and olfactory bulb (55) and, more recently, in the olfactory cortex of rodents, where they appear to participate in both detoxification and olfactory signal termination (56) . Here, we show that UGT1A6 is expressed in neurons of the human cerebral cortex and may be considered as a candidate for assisting in the detoxification of chemicals triggering cortical OR activation.
Bitter taste receptors are also expressed in several brain regions of the rat, and they appear to be functional (57, 58) . Several taste receptor mRNAs are also detected in the present study in the human frontal cortex. However, evidence of protein expression of taste receptors and expression of the specific gustatory specific G protein, >-gustducin, in the human brain is still needed but is beyond the scope of the present study. Alpha-gustducin plays a crucial role in peripheral taste signaling transduction in sensory gustatory cells (59, 60) .
As of now, we have no precise idea about the role of ORs in the human cerebral cortex and what might be the nature of the putative ligands of cortical ORs or the routes that ligands may use to contact the corresponding ORs in the cerebral cortex. Several natural ligands have been identified in mammals (61Y67). These are small molecules of approximately 200 to 400 molecular weight related to steroids, fatty acid derivatives, and various terpenoid compounds (67Y79). However, it is not known whether central ORs are functionally related to their putative counterparts within the sensory olfactory neurons. It is possible that putative exogenous ligands to ORs in the human brain are transported through the blood vessels and the extracellular space. Alternatively, brain ORs might be stimulated by local chemicals from neighboring cells, or even from the same cells, thus having a self-stimulating mechanism regulating internal trafficking.
In line with these hypotheses, ORs have been involved in functions other than olfactory signal recognition, including axonal guidance (80Y82), and cell assembly functions in the embryonic period (83) , muscle regeneration, and regulation of cell adhesion and migration (84, 85) . Olfactory receptor expression in the testis has been implicated in sperm chemotaxis (86Y88). Regarding the nervous system, expression of ORs in ganglia of the autonomic nervous system has lent support to the idea that they serve functions other than odorant detection (89) , including detection of endogenously produced chemicals in their vicinity (31) . G>olf is expressed in different brain regions in the murine brain (16, 90) . It is worth noting that surviving homozygous mice with null mutation in G>olf exhibit, in addition to reduced olfaction, hyperactive behaviors. These behavioral phenotypes suggest that G>olf may also function as an essential signaling molecule more centrally in the brain (16) .
A particularly exciting and fortuitous observation of the present study is that ORs are dysregulated in the PD frontal cortex. It is worth stressing that PD cases did not (with 1 exception) experience gross cognitive deficits, and Lewy bodies in frontal cortex were absent (cases categorized as stage 3 and 4) or present in small numbers (cases categorized as stage 5). Importantly, OR dysregulation occurred in cases at premotor and at parkinsonian stages of the disease. This suggests that OR dysregulation may occur at relatively early stages of PD pathology and that it has no relation with drug therapy because the premotor cases had not received any anti-parkinsonian medication.
Results from the present mRNA arrays and TaqMan PCR analyses have relevant implications. First, dysregulation of ORs in the frontal cortex area 8 appears at relatively early stages of the neurodegenerative processes, along with other molecular changes (32, 33, 35) , and precedes the presence of >-synuclein aggregates. Second, OR dysregulation is not related to medication because it was found in patients who had not received drug therapy. Third, there is a predominant OR downregulation in PD, which seems not to be a consequence of a more general downregulation of other central chemoreceptors because certain TASRs appeared to be upregulated in the same region at the same stages of the process in the same cases. Fourth, downregulation of certain ORs in PD is probably sex-dependent because a significant decrease in the expression of, at least, certain genes was found mostly in men but not in women. Unfortunately, lack of appropriate antibodies against the products of dysregulated genes did not permit the validation of RNA dysregulation at the protein levels.
Sex differences have been largely recognized in relation to olfactory signaling (91) . These are partly caused by sexually dimorphic olfactory response despite similar olfactory circuits, suggesting that sex-specific initial signals prompt divergent behaviors (92) . This may be caused by specific sex responses to sexually dimorphic specific ligands (93Y95) and to the imprinting of sex-dimorphic sensory olfactory modulation by hormones (96Y101). The present findings indicate sex-specific vulnerability of certain ORs in PD, thus suggesting that at least a subpopulation of cortical ORs is modulated by steroid hormones or their derivatives.
Olfaction is altered in PD even at early premotor stages of the degenerative process (102, 103) . Most information regarding smell disorders in neurodegenerative diseases, and particularly PD, is focused on the presence of altered molecules in the olfactory tract (i.e. >-synuclein in PD) and the altered complex functional connectivity of primary and secondary central olfactory areas (102) . Interestingly, although less frequent than impairment of smell, taste function is also impaired in PD, and altered taste mainly involves perception of bitter (104, 105) . Unfortunately, nothing is known at present about the vulnerability of peripheral sensory olfactory and taste receptors in the nasal cavity and tongue, respectively. Therefore, it may be premature and perhaps incorrect to suggest that impaired olfaction and taste perception constitute a part of a more extended dysregulation of OR and taste pathways involving specific sensory peripheral and random central cortical neurons. Rather, the consequences of dysregulation of ORs and TASRs in the frontal cortex area 8 in PD might not have any relation with sensory organs. It is clear that further study is needed to unveil the function of these new putative central chemoreceptors or signaling systems in the CNS.
In summary, the present observations demonstrate for the first time the expression of several ORs and TASRs in the human brain. For the present purposes, the presence of ORs has been demonstrated at mRNA and protein levels in frontal cortex, and it is accompanied by the expression of obligate functional molecules of the OR pathway, AC3 and G>olf, and putative OR transporters RTP1, RTP2, and REEP1. These findings lend weight to the idea that ORs (and probably TASRs) in the human brain may support key physiologic roles, and they suggest a new scenario in the still poorly understood chemical signaling system of the brain. Regarding the vulnerability of ORs and TASRs in pathologic conditions, the present findings show dysregulation of certain members in the frontal cortex area 8 in PD. Studies are needed to prove regional differences in PD and assessment of OR and TASR expression in other neurodegenerative disorders, in addition to gaining knowledge about the functional implications of these central neurochemical receptors. This represents a stimulating insight in the field of human neuropathology.
